Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor...

effectiveness of everolimus in carcinoid tumors have not been established. sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated...

cytokine therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear...

(NSCLC). Sunitinib is an oral drug that inhibits the phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF. Sunitinib is used in...

shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent). Sugen was founded in 1991 in Redwood City, California, by veteran...

small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF...

inhibitor that is effective both as a senolytic and as therapy for CML. Sunitinib, an inhibitor of the receptors for FGF, PDGF and VEGF is also based on...

phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine...

randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC). Sharma...

tyrosine kinase inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31  The effectiveness of imatinib and sunitinib depend on the genotype...